REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Rhea-AI Summary

REGENXBIO (NASDAQ: RGNX) announced a conference call scheduled for February 28, 2023, at 4:30 p.m. ET. This call will cover the company’s financial results for Q4 and the full year ended December 31, 2022, along with recent operational highlights.

REGENXBIO, a clinical-stage biotechnology company, focuses on gene therapy through its proprietary NAV Technology Platform, which comprises over 100 novel AAV vectors. The company aims to advance five AAV Therapeutics into pivotal-stage or commercial products by 2025.

Positive

• Proprietary NAV Technology Platform features over 100 novel AAV vectors.
• Focus on advancing five AAV Therapeutics to pivotal-stage or commercial products by 2025.

Negative

• None.

ROCKVILLE, Md., Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2022, and recent operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9, and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5 x '25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-february-28-to-discuss-fourth-quarter-and-full-year-2022-financial-results-and-recent-operational-highlights-301751462.html

SOURCE REGENXBIO Inc.

FAQ

What is REGENXBIO's upcoming conference call about?

REGENXBIO's conference call will discuss its financial results for Q4 and the full year ended December 31, 2022, and recent operational highlights.

When is REGENXBIO's conference call scheduled?

The conference call is scheduled for February 28, 2023, at 4:30 p.m. ET.

What platforms does REGENXBIO use for gene therapy?

REGENXBIO utilizes its proprietary NAV Technology Platform, which consists of more than 100 novel AAV vectors.

What is REGENXBIO's strategic goal by 2025?

REGENXBIO aims to progress five AAV Therapeutics from its pipeline into pivotal-stage or commercial products by 2025.